GET DAILY SIGNALSWhy Is Adaptive Biotechnologies (ADPT) Stock Down -0.18% Today?
Key Takeaways
- Adaptive Biotechnologies shares slipped 0.18% on Friday, closing at $22.27 versus the prior session's close of $22.31.
- The modest decline extends a broader cooling-off pattern after the stock surged roughly 107% over the past year and hit a 52-week high of $23.15 in mid-July.
- Heavy insider selling — including an $8.5 million disposition by Chief Scientific Officer Harlan Robins — has cast a shadow over the stock's otherwise strong fundamental narrative.
- Analysts remain cautiously constructive with a consensus "Moderate Buy" rating, though the average price target of approximately $22.29 leaves limited near-term upside.
- The company's Q2 2026 earnings report, scheduled for July 29 after market close, stands as the next major catalyst.
- Traders are watching whether the MRD business can sustain its momentum and whether the planned MRD–Immune Medicine separation unlocks additional value.
Opening Summary
ADPT — Adaptive Biotechnologies Corporation, the Seattle-based commercial-stage biotechnology company known for its immune medicine platform and clonoSEQ MRD diagnostic test — saw its shares edge lower on Friday, closing the final session of the week at $22.27, down $0.04 from the previous close of $22.31. The 0.18% dip, while small in isolation, extended a period of consolidation and selective profit-taking after a blistering rally that carried the stock from its 52-week low of $9.96 to as high as $23.15. After-hours trading showed a modest bounce to $22.60, suggesting some dip-buying interest ahead of the weekend. The incremental decline reflects a market that is reassessing valuation and insider activity even as the company's core growth story remains intact.
Profit-Taking After a Historic Rally
The dominant theme behind recent sessions for ADPT is not a breakdown in fundamentals but rather the natural gravitational pull that follows an extraordinary run. Over the trailing 12 months, Adaptive Biotechnologies delivered a total return exceeding 100%, driven by accelerating MRD test volumes, raised full-year revenue guidance to $260 million–$270 million, and mounting enthusiasm around the planned separation of its MRD and Immune Medicine business units. The stock's 50-day simple moving average of roughly $17.76 and its 200-day moving average near $16.25 underscore just how far and fast shares have climbed. When a stock more than doubles in a year, even incremental selling pressure — whether from institutions rebalancing or retail traders locking in gains — can produce visible softness, and that is precisely what the tape showed on Friday.
Insider Selling Overhang Weighs on Sentiment
Perhaps the most persistent headwind for ADPT in recent weeks has been the wave of insider selling. According to SEC filings, company insiders have sold approximately $62 million worth of stock over the past six months, with zero open-market purchases recorded during that same window. The highest-profile transaction came on July 2, when Chief Scientific Officer Harlan S. Robins — brother of CEO Chad Robins — liquidated 386,240 shares for roughly $8.5 million at a weighted average price of $22.01. Other executives, including Chief People Officer Francis Lo and Chief Commercial Officer Sharon Benzeno, have also trimmed positions meaningfully. While all sales were executed under pre-arranged Rule 10b5-1 trading plans — and thus not indicative of any non-public information — the sheer scale and one-sided nature of insider activity has given some investors pause, particularly as the stock approached its 52-week highs.
Valuation Questions Creep In
As ADPT climbed toward $23, valuation metrics began to look stretched by several conventional measures. The stock trades at a price-to-sales ratio of approximately 11.8x, well above the life sciences industry average of roughly 4.2x and even above peer-group multiples near 9.5x. While premium multiples can be justified by rapid revenue growth — first-quarter revenue rose 35.1% year-over-year to $70.87 million — the company remains unprofitable, posting a net loss of $49.7 million over the trailing twelve months. The $300 million convertible senior notes offering earlier this year also introduced potential dilution risk. This combination of a rich multiple and continued cash burn has prompted some investors to question whether the rally had gotten ahead of itself, contributing to the recent sideways-to-slightly-lower drift.
Market Context and Trading Activity
Friday's session saw roughly 2.82 million shares change hands, roughly in line with the 10-day average volume of 2.61 million — indicating no panic selling but also no surge of bargain-hunting. The intraday range spanned from $21.83 to $22.77, reflecting continued two-way uncertainty. Broader biotech and life sciences indices were mixed, and the stock's beta of 2.07 means it remains significantly more volatile than the broader market. Notably, ADPT has held above its 50-day moving average throughout the recent pullback, suggesting that the longer-term technical uptrend remains intact for now, even as near-term momentum has cooled. After-hours action, which pushed shares to $22.60, hints that some traders see the modest decline as an opportunity rather than a warning sign.
What Comes Next for ADPT
All eyes now turn to Wednesday, July 29, when Adaptive Biotechnologies reports second-quarter 2026 financial results after the market close. Analysts expect a loss of approximately $0.13 per share on revenue of roughly $66.27 million. The print will be scrutinized for MRD clinical testing volume trends, average selling price trajectory, and any updates on the timeline and structure of the MRD–Immune Medicine separation. Management's commentary on the path to positive adjusted EBITDA and free cash flow — both targeted by year-end 2026 — will also be critical. On the analyst front, TD Cowen recently raised its price target to $25, while Morgan Stanley sits at $20 with an Equal Weight rating, reflecting the divided views on Wall Street. The earnings call could either validate the bull case and reignite momentum, or confirm the bears' view that the stock has run too far, too fast.
Trending AI Robots
For investors seeking a systematic, data-driven approach to navigating volatile stocks like Adaptive Biotechnologies, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron provides hundreds of AI trading bots that span thousands of tickers, but only those demonstrating the strongest performance under current market conditions are featured in this dynamically updated section. Bots vary by trading strategy, timeframe, performance metrics, and the symbols they trade, giving users the flexibility to find an approach that matches their own investment style. Explore the Trending AI Robots page to discover which strategies are currently leading the pack.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
Momentum Indicator for ADPT turns positive, indicating new upward trend
ADPT saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 75 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ADPT just turned positive on October 27, 2026. Looking at past instances where ADPT's MACD turned positive, the stock continued to rise in 45 of 54 cases over the following month. The odds of a continued upward trend are 83%.
ADPT moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ADPT crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +12.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADPT advanced for three days, in 237 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
ADPT broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ADPT entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.246) is normal, around the industry mean (67.298). P/E Ratio (-69.950) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (13.966) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ADPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development of an immune medicine platform
Industry MedicalSpecialties
Advertisement